The estimated Net Worth of Fund V, L.P.Omega Fund V Gp... is at least $49.8 Million dollars as of 29 April 2021. Fund Gp owns over 17,158 units of Gossamer Bio stock worth over $1,841,333 and over the last 6 years Fund sold GOSS stock worth over $47,972,724.
Fund has made over 42 trades of the Gossamer Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently Fund sold 17,158 units of GOSS stock worth $937,685 on 29 April 2021.
The largest trade Fund's ever made was selling 112,776 units of Gossamer Bio stock on 10 September 2019 worth over $2,393,107. On average, Fund trades about 25,977 units every 14 days since 2019. As of 29 April 2021 Fund still owns at least 2,068,913 units of Gossamer Bio stock.
You can see the complete history of Fund Gp stock trades at the bottom of the page.
Over the last 6 years, insiders at Gossamer Bio have traded over $10,765,709 worth of Gossamer Bio stock and bought 2,039,396 units worth $4,494,757 . The most active insiders traders include Kristina Burow, Faheem Hasnain, and Fund V, L.P.Omega Fund V Gp.... On average, Gossamer Bio executives and independent directors trade stock every 33 days with the average trade being worth of $40,853. The most recent stock trade was executed by Richard Aranda on 24 June 2024, trading 1,908 units of GOSS stock currently worth $1,259.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio executives and other stock owners filed with the SEC include: